NeoGenomics, Inc.: NeoGenomics Liquid Biopsy Subsidiary Iniv

FT. MYERS, FL / ACCESSWIRE / May 10, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced

Related Keywords

Fort Myers , Florida , United States , Georgia , Tampa , North Carolina , United Kingdom , Texas , Research Triangle Park , Atlanta , California , San Diego , Tennessee , Singapore , Houston , Aliso Viejo , Cambridge , Cambridgeshire , Switzerland , American , Charlie Eidson , Karen Chandler Smith , Inivata Invision , Doug Brown , Company Invisionfirst , Cancer Research United Kingdom Cambridge Institute , American Society Of Clinical Oncology , Neogenomics Inc , Inivata Limited , Company Pharma Services Division , Nasdaq , University Of Cambridge , While The Company , Company Annual Report On Form , Corporate Development , Consilium Strategic Communications , American Society , Clinical Oncology , Annual Meeting , Chief Medical Officer , Saturday June , Liquid Biopsy , Minimal Residual Disease Detection , Neck Squamous Cell Carcinoma , Pharma Services Division , Privacy Practices , Breakthrough Device Designation , Private Securities Litigation Reform Act , Annual Report , Corporate Development Officer , Investor Relations , Media Contacts , Neogenomics , Liquid , Biopsy , Ubsidiary , Inivata , Collaborators , Present , Data , Urther , Invalidating , Application , Radar , Nvisionfirst , Young , Tests , 022 , Disco , Nnual , Meeting ,